0
0
NEW DELHI — In a landmark address that signals a paradigm shift for the nation’s scientific landscape, Union Minister Dr. Jitendra Singh declared this week that India has successfully transitioned from a global follower to a primary setter of benchmarks in healthcare, space, and innovation. Speaking at the Bharatiya Vigyan Sammelan 2025, Singh highlighted a decade of structural reforms that have catapulted India into the top tier of global health leaders, moving beyond its traditional role as a manufacturer of affordable generics to a pioneer in cutting-edge medical technology and preventive care.
The Minister’s remarks come at a pivotal moment. As of late 2025, India has not only sustained its title as the “Pharmacy of the World”—supplying over 60% of the world’s vaccines—but has also emerged as a hub for high-end biomanufacturing and digital health infrastructure that many developed nations are now looking to emulate.
A Decade of Transformation: By the Numbers
The statistics backing this claim are significant. Since 2014, India’s ranking in the Global Innovation Index (GII) has climbed from 81st to 38th. This ascent is mirrored in the domestic startup ecosystem, which has grown from roughly 400 startups a decade ago to nearly 200,000 today, many of which are focused on MedTech and biotechnology.
“Science in India is no longer confined to the laboratory,” Dr. Singh stated. “It is now a tool for enhancing the ‘ease of living.’ From indigenous DNA vaccines to affordable medical implants exported to 100 countries, our innovation ecosystem has earned international trust.”
Key milestones highlighted in the 2024-2025 period include:
-
The TB Decline: According to the World Health Organization’s (WHO) Global TB Report 2025, India recorded a 21% decline in tuberculosis incidence since 2015—nearly double the global rate of decline (12%).
-
Digital Health Scale: The Ayushman Bharat Digital Mission (ABDM) has now crossed 730 million health accounts (ABHA), creating the world’s largest integrated digital health database.
-
Pharma Growth: The Indian pharmaceutical sector reached a valuation of $50 billion in FY 2024, with exports accounting for more than half of that figure ($26.5 billion).
From Generics to Gene Therapy
While India’s ability to produce low-cost medicine is well-documented, the current shift is toward “value-driven” innovation. Dr. Singh pointed to the development of the world’s first gene therapy for hemophilia and the launch of the first indigenous antibiotic for complicated urinary tract infections as evidence of this evolution.
Furthermore, the medical device sector—traditionally an import-heavy industry—is undergoing a revolution via the Production Linked Incentive (PLI) scheme. Domestic companies are now manufacturing high-complexity equipment such as MRI machines, CT scanners, and radiotherapy devices for cancer care. Projections suggest this sector could grow from $15 billion today to $50 billion by 2030
“The boundary between public and private sectors has faded,” Singh noted, emphasizing that the “siloed” approach to research is over. The integration of basic science with clinical research is now the standard, supported by a nearly tenfold increase in government funding for health programs over the last nine years.
Expert Perspectives: A Balanced View
Independent experts acknowledge the progress but urge cautious optimism. Dr. C.N. Manjunath, a Member of Parliament and renowned cardiologist, noted at the Bengaluru Diabetes Conference that while indigenous R&D is succeeding, the “next frontier is ensuring these innovations reach the last mile in rural India.”
Public health analysts also point to the WHO’s 2025 report, which, while praising India’s progress in TB reduction, noted that the country is still unlikely to meet its ambitious goal of total elimination by 2025. Challenges such as multi-drug-resistant (MDR) TB and regional inconsistencies in drug supply chains remain hurdles.
“India’s digital health infrastructure is a global pathfinder,” says a recent report from the World Economic Forum. However, the report also highlights that “data privacy, security, and bridging the digital divide for the elderly and low-income populations remain critical priorities.”
What This Means for the Global Consumer
For the average citizen, both in India and abroad, this “benchmark setting” translates to more than just national pride; it means affordability. With the patent expiration of several major anti-obesity and diabetes drugs (such as semaglutide) expected in early 2026, Indian generic manufacturers like Cipla and Dr. Reddy’s are poised to launch versions that are 50% to 85% cheaper than current brand-name options.
For healthcare providers, the Ayushman Bharat Digital Mission is simplifying patient history tracking. With over 178,000 Ayushman Arogya Mandirs (primary health centers) now operational, preventive screenings for hypertension and diabetes are becoming a standardized part of rural life.
The Road Ahead
As India moves into 2026, the focus appears to be on “Vishwabandhu Bharat”—a commitment to global welfare. Whether it is through the export of affordable implants or the sharing of digital health open-source platforms, the nation is positioning itself as a leader that provides solutions not just for the elite, but for the global south.
“The world’s outlook towards India has changed,” concluded Dr. Singh. “We are no longer just participating in global benchmarks; we are defining them.”
Reference Section
- https://tennews.in/india-now-sets-global-benchmarks-in-space-defence-health-and-innovation-jitendra-singh/
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
